Alligator Bioscience appoints Johan Giléus as CEO

5 October 2026

Swedish immuno-oncology firm Alligator Bioscience (STO: ATORX) has announced the appointment of Johan Giléus as Alligator’s new chief executive (CEO), effective 1 January 2027.

The appointment follows Alligator’s strategic refocusing towards its financial interest in HLX22, as announced on July 23, 2026. Johan Giléus succeeds Søren Bregenholt, who will remain CEO until December 31, 2026. Johan Giléus will continue in parallel as CFO. Following the transition, Alligator will operate with a minimal organisation, supported by the Board of Directors and external consultants.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology